Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 21, 2007
Reporting Period: This filing serves as a notice of the Annual General Meeting of Shareholders scheduled for July 31, 2007. It incorporates a press release and proxy statement detailing corporate governance proposals, director elections, and executive compensation adjustments. The filing does not contain a financial report for a specific fiscal period but references share counts as of May 31, 2007.
Key Financial Metrics and Capital Structure
The filing text does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. However, the following capital structure and compensation data are disclosed:
- Outstanding Shares: 28,162,202 Ordinary Shares (as of May 31, 2007).
- Nominal Value: NIS 0.01 per share.
- Authorized Capital: NIS 500,000 divided into 50,000,000 Ordinary Shares.
- Major Shareholders (as of April 16, 2007):
- AXA Assurances I.A.R.D. Mutuelle: 17.3% (4,650,957 shares)
- Clal Biotechnology Industries Ltd: 10.85% (3,056,274 shares)
- Martin S. Gerstel (Chairman): 6.05% (1,702,568 shares)
- Proposed Director Compensation:
- Annual Retainer: $10,000 USD.
- Committee Service: Additional $5,000 USD annually.
- Meeting Fees: $1,000 USD per day (or $500 USD for meetings under 4 hours).
- Stock Options: Initial grant of 40,000 shares per non-management director; annual grants of 10,000 shares thereafter.
- Proposed Chairman Compensation: Grant of 500,000 stock options (vesting monthly over 4 years) with no cash compensation. Options are exercisable only if the share price exceeds $10.00.
- Proposed CEO Compensation Adjustment: Issuance of shares valued at approximately $28,000 to replace a portion of the CEO's 2006 cash salary, plus a cash bonus grossed up for taxes.
Material Changes and Corporate Actions
The filing outlines several material changes to corporate governance and compensation structures to be voted upon by shareholders:
- Board Composition: Election of seven directors, including three new external directors (Prof. Yair Aharonowitz, Dr. Arie Ovadia, Prof. Joshua Shemer) to comply with Israeli Companies Law requirements.
- Compensation Restructuring: Implementation of a new cash and stock option plan for non-management directors and a specific stock-only compensation package for the Chairman.
- CEO Compensation: Modification of the CEO's 2006 compensation to include share issuance in lieu of cash salary.
- Articles of Association: Adoption of amended and restated Articles to align with recent changes in the Israeli Companies Law.
- Indemnification: Approval of a $5,000,000 aggregate limit for indemnifying and exculpating office holders.
- Auditor Appointment: Re-appointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) for the fiscal year ending December 31, 2007.
Guidance, Outlook, and Risks
Management Commentary: The Board emphasizes that the Company's success depends significantly on the participation of non-management directors and the performance of the Chairman and CEO. The proposed compensation structures are designed to align interests with shareholders and retain key leadership.
Risks and Contingencies:
- Quorum Risk: The meeting requires a quorum of shareholders holding at least 33.33% of voting rights. If not met within 30 minutes, the meeting will be adjourned to August 7, 2007.
- External Director Election Thresholds: The election of external directors requires a majority vote that includes at least one-third of the voting power of non-controlling shareholders, or opposition from non-controlling shareholders must not exceed 1% of total voting power.
- Share Price Condition: The Chairman's stock options are contingent on the share price reaching $10.00, creating a potential barrier to exercising these options if the market price remains below this threshold.
Key Facts for Investor Verification
- Verify the current share price relative to the $10.00 exercise price threshold for the Chairman's proposed 500,000 options.
- Confirm the voting requirements for external directors, specifically the "non-controlling shareholder" support threshold.
- Review the dilution impact of the proposed option grants to directors (40,000 initial + 10,000 annual per director) and the Chairman (500,000 total).
- Check the status of the CEO's 2006 salary adjustment and the issuance of "Cash Replacement Shares."
- Monitor the outcome of the July 31, 2007 Annual General Meeting regarding the adoption of the amended Articles of Association.